| US 7,589,105 B2 | ||
| Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | ||
| Masaki Meguro, Tokyo (Japan); Tomiichiro Oda, Tokyo (Japan); Yasuhiro Nakagami, Tokyo (Japan); Shinji Marumoto, Tokyo (Japan); Kazuo Koyama, Tokyo (Japan); and Isao Kaneko, Tokyo (Japan) | ||
| Assigned to BTG International Limited, London (United Kingdom) | ||
| Appl. No. 10/497,183 PCT Filed Nov. 25, 2002, PCT No. PCT/JP02/12265 § 371(c)(1), (2), (4) Date Oct. 19, 2004, PCT Pub. No. WO03/045923, PCT Pub. Date Jun. 05, 2003. |
||
| Claims priority of application No. 2001-361847 (JP), filed on Nov. 28, 2001; and application No. 2002-192777 (JP), filed on Jul. 02, 2002. | ||
| Prior Publication US 2005/0054732 A1, Mar. 10, 2005 | ||
| Int. Cl. A01N 43/60 (2006.01); A01N 43/42 (2006.01) | ||
| U.S. Cl. 514—310 [514/248; 544/240] | 10 Claims |
1. A pharmaceutical composition for the treatment of amyloidosis which contains, as an active ingredient, at least one nitrogen-containing
heteroaryl compound represented by the following general formula (I)
 wherein
R1 and R2 each independently represent a hydrogen atom or a C1-6 alkyl group,
Z1 and Z2 each independently represent a hydrogen atom, C1-6 alkyl group, C1-6 alkoxy group, halo-C1-6 alkyl group or halogen atom,
Z3 represents a C1-6 alkoxy group, mercapto group, C1-6 alkylthio group, amino group, mono- or di-C1-6 alkylamino group, hydroxy group or halogen atom,
Z4 and Z5 each independently represent a hydrogen atom or halogen atom, and
A represents a group of formula (VI) below
 wherein
R10 and R11 each independently represent a hydrogen atom, C1-6 alkyl group, C1-6 alkoxy group, C1-6 alkylthio group, or mono- or di-C1-6 alkylamino group, or pharmacologically permitted salt thereof.
|